Disclosed positions

Estimated from their latest filings — positions may have changed since

Stock	Shares	Price	Value	Weight	As of
RNAAtrium Therapeutics, Inc.	49,797	—	—		2026-01-07

RNA

Atrium Therapeutics, Inc.

—

49,797 sh

All filings on record

Every Form 4 transaction we track for this filer

all 4buys 0sells 1

Stock	Transaction	Date	~6mo later
RNAMAvidity Biosciences, Inc.	Return — · 98,547 sh	2026-02-27	—
RNAAtrium Therapeutics, Inc.	Sell $269.2K · 3,727 sh	2026-01-07	—
RNAAtrium Therapeutics, Inc.	Tax $699.0K · 9,726 sh	2025-12-17	—
RNAAtrium Therapeutics, Inc.	Grant — · 23,250 sh	2025-12-17	—

RNAMReturn

2026-02-27 · Avidity Biosciences, Inc.

98,547

—

RNASell

2026-01-07 · Atrium Therapeutics, Inc.

$269.2K

—

RNATax

2025-12-17 · Atrium Therapeutics, Inc.

$699.0K

—

RNAGrant

2025-12-17 · Atrium Therapeutics, Inc.

23,250

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.